• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Motesanib Diphosphate

Motesanib Diphosphate

Product ID M5877
Cas No. 857876-30-3
Purity ≥98%
Product Unit SizeCostQuantityStock
5 mg $109.80 In stock
25 mg $379.70 In stock
50 mg $590.70 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Motesanib is an inhibitor of VEGFR 1/2/3, PDGFR, c-Kit, and RET that displays anticancer chemotherapeutic and anti-angiogenic activities. In vivo, motesanib inhibits tumor growth of xenografts of various cancers. Motesanib is currently in clinical trials as a potential treatment for non-small cell lung cancer (NSCLC), breast cancer, and medullary thyroid cancer.

Product Info

Cas No.

857876-30-3

Purity

≥98%

Formula

C22H23N5O • 2H3PO4

Formula Wt.

569.44

IUPAC Name

N-(3,3-Dimethyl-2,3-dihydro-1H-indol-6-yl)-2-[(4-pyridinylmethyl)amino]nicotinamide phosphate (1:2)

Synonym

AMG-706; AMG706; AMG 706

Solubility

DMSO 100 mg/mL warmed (175.61 mM) Water 19 mg/mL warmed (33.36 mM) Ethanol Insoluble

Appearance

Pale yellow powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

M5877 MSDS PDF

Info Sheet

M5877 Info Sheet PDF

References

Ellis PM, Al-Saleh K. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions. Crit Rev Oncol Hematol. 2012 Oct;84(1):47-58. PMID: 22405734.

Coxon A, Ziegler B, Kaufman S, et al. Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Mol Cancer. 2012 Sep 19;11:70. PMID: 22992329.

Coxon A, Bready J, Kaufman S, et al. Anti-tumor activity of motesanib in a medullary thyroid cancer model. J Endocrinol Invest. 2012 Feb;35(2):181-90. PMID: 21422803.

Raghav KP, Blumenschein GR. Motesanib and advanced NSCLC: experiences and expectations. Expert Opin Investig Drugs. 2011 Jun;20(6):859-69. PMID: 21534718.

Polverino A, Coxon A, Starnes C, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006 Sep 1;66(17):8715-21. PMID: 16951187.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • R2714

    Recombinant HCV-NS5 Antigens

    Recombinant HCV antigen fragment.

    ≥95%
  • C0262

    L-Carnitine

    Endogenous quaternary ammonium, required for fa...

    ≥98%
  • A6932

    Aristolochic Acid A

    Found in Aristolochia and Radix; PLA2 inhibitor...

    ≥95%
  • V3455

    Vinpocetine

    Targets nuclear factor kappa B activation.

    ≥98%
  • T3035

    Thienylheptyl Isothiocyanate

    Thienylbutyl ITC analog.

    ≥95%
  • S0049

    Salmon Calcitonin Acetate

    Peptide, involved in feeding behavior and insul...

    ≥95%
  • G1745

    Gemcitabine Hydrochloride

    Nucleoside (deoxycytidine) analog; ribonucleoti...

    ≥98%
  • B030962

    BAY-1251152

    Inhibitor of PTEFb/CDK9.

    ≥98%
  • L5660

    Loperamide Hydrochloride

    FIASMA, μOR agonist, potential HCN channel blo...

    ≥98%
  • O8500

    Ovalbumin Fragment (257-264)

    OVA antigen.

    ≥98%
  • D1769

    Dermorphin

    Opioid peptide; μOR agonist.

    ≥96%
  • A044178

    Abemaciclib mesylate

    CDK inhibitor.

    ≥98%
  • P5712

    Podophyllotoxin

    Non-alkaloid lignan found in Podophyllum,deriva...

    ≥90%
  • S6019

    Speract

    Peptide, derived from egg outer envelope; K+ ch...

    ≥95%
  • P3209

    Piceatannol

    Polyphenolic hydroxystilbene, resveratrol deri...

    ≥99%
  • C5647

    Colistin Sulfate

    Polymixin, antimicrobial peptide, induces forma...

    Biological Potency: ≥19366 IU/mg
  • P0369

    Parecoxib Sodium

    NSAID; COX-2 inhibitor.

    ≥99%
  • P9870

    Pyridostatin Hydrochloride

    G-quadruplex ligand; DNA breakage inducer.

    ≥97%
  • A5031

    4-Aminophenylphosphate Disodium

    Alkaline phosphatase substrate used to quantify...

    ≥98%
  • A4924

    AMG-208

    c-MET and Ron inhibitor.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only